)
Visual
earnings real time
CelLBxHealth
CelLBxHealth (AGL) investor relations material
CelLBxHealth Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary16 Jan, 2026
Executive summary
Preliminary unaudited Q4 and FY2025 revenues expected at approximately £1.4 million, with biopharma and product revenues at £0.3 million for the year.
Some sales contracts worth £0.2 million were deferred to Q1 2026 due to ongoing restructuring.
Cash balance at year-end 2025 was £7.3 million, supporting ongoing strategic initiatives.
Financial highlights
FY2025 revenues fell short of the £1.6 million target due to contract deferrals.
Biopharma and product revenues contributed £0.3 million to the full year.
Cash position remains strong at £7.3 million as of December 31, 2025.
Outlook and guidance
Focused on delivering commercial milestones from a qualified 2026 pipeline valued at £12.6 million (risk-weighted at £4.5 million).
Cost-saving and restructuring measures are expected to drive improved performance in 2026.
Impact of £5.9m savings on 2026 cash runway
How will deferred sales affect 2026 pipeline conversion?
Impact of OTCQX delisting on market visibility
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- CMBT
Q1 profit, Golden Ocean merger, and decarbonization drive strong outlook. - CBT
Adjusted EPS down 13% to $1.53 as Battery Materials growth offset Reinforcement Materials decline. - ADVENZYMES
Q3 FY26 revenue up 2% YoY, PAT up 11%, with wind power SPV investment approved. - SIMO
Q4 2025 revenue and margins surged on SSD, eMMC/UFS, and automotive growth; 2026 outlook strong. - FSV
Annual revenue up 5% to $5.50B; Adjusted EBITDA and EPS both saw double-digit growth. - QLINEA
Over 400% revenue growth in 2025, with US expansion and breakeven targeted for 2027. - OMV
Clean CCS Operating Result down 10% year-over-year, with strong cash flow and 9.3% dividend yield. - UPM
Strong Q4 cash flow and strategic moves support growth despite lower sales and EBIT. - GSK
7% sales growth and 12% EPS rise, led by Specialty and HIV, with strong 2026 outlook. - UBSG
Net profit surged 56% YoY, with accelerated capital repatriation and robust capital ratios.
Next CelLBxHealth earnings date
H2 202529 May, 2026
CelLBxHealth
Next CelLBxHealth earnings date
H2 202529 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
ANGLE plc is a British medical diagnostics company focused on developing liquid biopsy solutions for cancer diagnostics. The company’s proprietary Parsortix system enables the capture and analysis of circulating tumor cells (CTCs) from patient blood samples, allowing for non-invasive cancer detection, monitoring, and personalized treatment insights. ANGLE’s technology is used in clinical research and trials, supporting advancements in oncology by providing real-time data on tumor progression and response to therapy. The company is headquartered in Guildford, United Kingdom, and its shares are listed on the London Stock Exchange and the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage